NCT06769152View on ClinicalTrials.gov

A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic CC Failed or Intolerance to Standard Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

June 5, 2027

Conditions
Cervical Cancers
Interventions
DRUG

HLX43 DOSE 1

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

DRUG

HLX43 DOSE 2

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

DRUG

HLX43 DOSE 3

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Trial Locations (1)

Unknown

RECRUITING

Shandong Cancer Hospital, Ji'nan

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY